Mastodon

Krashaemodes 8000 (Solution) Instructions for Use

Marketing Authorization Holder

Kraspharma, PJSC (Russia)

ATC Code

B05AA (Blood substitutes and plasma preparations)

Dosage Form

Bottle Rx Icon Krashaemodes 8000 Infusion solution: 100 ml, 200 ml or 400 ml bottle 1 pc.

Dosage Form, Packaging, and Composition

Infusion solution 100 ml
Povidone (low molecular weight medical polyvinylpyrrolidone) with molecular weight 8000±2000 6 g
Sodium chloride 550 mg
Potassium chloride 42 mg
Calcium chloride 50 mg
Sodium bicarbonate 23 mg
Magnesium chloride anhydrous 500 mcg

100 ml – bottles (1) – cardboard packs.
200 ml – bottles (1) – cardboard packs.
400 ml – bottles (1) – cardboard packs.

Clinical-Pharmacological Group

Drug with detoxifying action for parenteral use

Pharmacotherapeutic Group

Detoxifying agent

Pharmacological Action

The action of the combination is due to the ability of low molecular weight polyvinylpyrrolidone to bind toxins circulating in the blood and rapidly remove them from the body. It most fully binds toxins circulating in the blood of patients with dysentery, salmonellosis, and food intoxications. In burn disease, toxins formed during the first 4-5 days of the disease are almost completely inactivated; toxins formed at later stages are neutralized significantly weaker.

Toxins formed in the body of patients with acute radiation sickness are not bound, although their elimination from the body may be accelerated.

It helps eliminate erythrocyte stasis in the capillaries, which develops during intoxication of any origin, leading to improved microcirculation. It enhances renal blood flow, increases glomerular filtration, and increases diuresis.

Pharmacokinetics

It is not metabolized in the body. It is rapidly excreted by the kidneys, 80% within 4 hours, and completely within 12-24 hours.

Indications

Shock (post-traumatic, postoperative, burn, hemorrhagic); intoxication (toxic diseases of the gastrointestinal tract, including dysentery, dyspepsia, salmonellosis; burn disease, radiation sickness and hemolytic disease, peritonitis, intestinal obstruction, thyrotoxicosis, liver diseases, sepsis, pneumonia; acute phase of myocardial infarction); toxemia of newborns; preeclampsia.

ICD codes

ICD-10 code Indication
A02 Other salmonella infections
A03 Shigellosis
A05 Other bacterial food poisonings, not elsewhere classified
A09 Other and unspecified gastroenteritis and colitis of infectious origin
A40 Streptococcal sepsis
A41 Other sepsis
B15 Acute hepatitis A
B16 Acute hepatitis B
B17 Other acute viral hepatitis
B18 Chronic viral hepatitis
E05 Thyrotoxicosis [hyperthyroidism]
I21 Acute myocardial infarction
J15 Bacterial pneumonia, not elsewhere classified
K56.6 Other and unspecified intestinal obstruction
K65.0 Acute peritonitis (including abscess)
K70 Alcoholic liver disease
K71 Toxic liver disease
K73 Chronic hepatitis, not elsewhere classified
K75 Other inflammatory liver diseases
O10-O16 Edema, proteinuria and hypertensive disorders during pregnancy, childbirth and the puerperium
P36 Bacterial sepsis of newborn
P55 Hemolytic disease of fetus and newborn
R54 Acute intoxication
R57.0 Cardiogenic shock
R57.1 Hypovolemic shock
R57.2 Septic shock
R57.8 Other types of shock
T30 Burns and corrosions of unspecified body region
T66 Unspecified effects of radiation (radiation sickness)
T79.4 Traumatic shock
ICD-11 code Indication
1A02 Intestinal infections due to Shigella
1A09.Z Salmonella infection, unspecified
1A1Z Bacterial foodborne intoxications, unspecified
1A40.Z Infectious gastroenteritis or colitis, unspecified
1E50.0 Acute hepatitis A
1E50.1 Acute hepatitis B
1E50.Z Acute viral hepatitis, unspecified
1E51.Z Chronic viral hepatitis, unspecified
1G40 Sepsis without septic shock
1G41 Sepsis with septic shock
4A85.00 Drug hypersensitivity-induced liver disease
5A02.Z Thyrotoxicosis, unspecified
8E61.0 Radiation-induced brain injury
8E61.1 Radiation-induced spinal cord injury
BA41.Z Acute myocardial infarction, unspecified
CA40.0Z Bacterial pneumonia, unspecified
DA91.Z Unspecified obstruction of small intestine
DB30.Z Unspecified obstruction of large intestine
DB94.Z Alcoholic liver disease, unspecified
DB95.Z Drug-induced or toxic liver disease, unspecified
DB97.2 Chronic hepatitis, not elsewhere classified
DB97.Z Inflammatory liver diseases, unspecified
DC50.0 Primary peritonitis
DC50.2 Peritoneal abscess
DC50.Z Peritonitis, unspecified
DE2Z Diseases of the digestive system, unspecified
JA2Z Edema, proteinuria, or hypertensive disorders in pregnancy, childbirth or the puerperium, unspecified
KA60 Fetal or neonatal sepsis
KA84.Z Hemolytic disease of fetus or newborn, unspecified
MG2A Frailty syndrome
MG40.0 Cardiogenic shock
MG40.1 Hypovolemic shock
MG40.Z Shock, unspecified
NE11 Burn of unspecified body region
NF00 Exposure to radiation, not elsewhere classified
NF0A.4 Traumatic shock, not elsewhere classified

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Administer intravenously by drip at a rate of 40-80 drops per minute.

Use an infusion set with an in-line filter and a polymer connection needle.

Determine the total dose based on the patient’s age and the severity of intoxication.

For adults, the typical single dose is 100 ml to 400 ml.

For pediatric patients, calculate the dose individually per body weight.

In cases of severe shock or profound intoxication, repeat infusions as clinically required.

Adjust the infusion rate to avoid a rapid drop in blood pressure or respiratory distress.

Do not exceed the recommended infusion speed.

Monitor blood pressure, heart rate, and respiratory function continuously during administration.

Discontinue the infusion immediately if signs of a hypersensitivity reaction occur.

The total daily volume and frequency of administration are determined by the treating physician.

Adverse Reactions

Possible decrease in blood pressure, tachycardia, difficulty breathing (with rapid administration), allergic reactions of varying severity (up to the development of anaphylactic shock); infection at the injection site, thrombosis or phlebitis spreading from the infusion site.

Contraindications

Intracranial hypertension; hemorrhagic stroke; condition after traumatic brain injury; chronic heart failure stage IIb-III; respiratory failure; severe allergic reactions; thromboembolism; oliguria, anuria, acute nephritis; bronchial asthma; phlebothrombosis; hypersensitivity to the components of the combination.

Use in Pregnancy and Lactation

The possibility of use depends on the dosage form used.

Use in Renal Impairment

Contraindicated in acute nephritis.

Pediatric Use

Use is possible according to the dosage regimen.

Special Precautions

During treatment, monitoring of blood pressure and the patient’s condition is necessary.

Drug Interactions

For extensive burns, it is combined with the administration of plasma, albumin, gamma globulin.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Rx Only

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

TABLE OF CONTENTS